Cerebrospinal fluid apolipoprotein e concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 29, Issue 1, 2014, Pages 54-60

  Schmidt, Christian ^a   Becker, Harry ^a   Zerr, Inga ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E; BENZODIAZEPINE DERIVATIVE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; MEMANTINE; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIOCHEMICAL COMPOSITION; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPENDENT VARIABLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE REGISTRY; DISEASE SEVERITY; EDUCATION; EXECUTIVE FUNCTION; FEMALE; GENDER; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; PATHOGENESIS; PHENOTYPE; PROTEIN BLOOD LEVEL; STATISTICAL MODEL; VELOCITY; YOUNG ADULT;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COGNITION DISORDERS; EDUCATIONAL STATUS; FEMALE; HUMANS; LINEAR MODELS; MALE; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84896705296     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513505133     Document Type: Article

References (37)

1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013 ; 80 (19). 1778-1783
2. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 ; 261 (5123). 921-923
3. Rogers J, Papassotiropoulos A. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007 ; 68 (4). 614-619
4. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009 ; 63 (3). 287-303
5. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012 ; 148 (6). 1204-1222
6. Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA. 2010 ; 107 (26). 12011-12016
7. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2000 ; 97 (6). 2892-2897
8. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991 ; 541 (1). 163-166
9. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA. 2001 ; 98 (15). 8838-8843
10. Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000 ; 47 (6). 739-747
11. Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci. 1997 ; 145 (1). 33-39
12. Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci Lett. 1997 ; 231 (3). 175-178
13. Hahne S, Nordstedt C, Ahlin A, Nybäck H. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci Lett. 1997 ; 224 (2). 99-102
14. Blennow K, Hesse C, Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport. 1994 ; 5 (18). 2534-2536
15. Lindh M, Blomberg M, Jensen M, et al. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett. 1997 ; 229 (2). 85-88
16. Pirttilä T, Koivisto K, Mehta PD, et al. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci Lett. 1998 ; 249 (1). 21-24
17. Song F, Poljak A, Crawford J, et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE. 2012 ; 7 (6). e34078
18. Gupta VB, Laws SM, Villemagne VL, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011 ; 76 (12). 1091-1098
19. Slooter AJ, de Knijff P, Hofman A, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett. 1998 ; 248 (1). 21-24
20. Liu M, Kuhel DG, Shen L, Hui DY, Woods SC. Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol. 2012 ; 303 (9). R903 - R908
21. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 ; 6 (8). 734-746
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984 ; 34 (7). 939-944
23. Aebi C Validierung der neuropsychologischen Testbatterie CERAD-NP: eine Multi-Center Studie. Switzerland: Faculty of Humanities, University of Basel ; 2002
24. Doody RS, Dunn JK, Huang E, Azher S, Kataki M. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004 ; 17 (1-2). 1-4
25. Crutcher K. Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease. J Mol Neurosci. 2004 ; 23 (3). 181-188
26. Veinbergs I, Everson A, Sagara Y, Masliah E. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J Neurosci Res. 2002 ; 67 (3). 379-387
27. Darreh-Shori T, Modiri N, Blennow K, et al. The apolipoprotein E â̂Š4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging. 2011 ; 32 (7). 1236-1248
28. Yamauchi K, Tozuka M, Nakabayashi T, et al. Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin Chem. 1999 ; 45 (4). 497-504
29. Andres MA, Feger U, Nath A, Munsaka S, Jiang CS, Chang L. APOE â̂Š 4 allele and CSF APOE on cognition in HIV-infected subjects. J Neuroimmune Pharmacol. 2011 ; 6 (3). 389-398
30. Wahrle SE, Shah AR, Fagan AM, et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007 ; 2: 7
31. Tai LM, Bilousova T, Jungbauer L, et al. Levels of soluble apolipoprotein E/amyloid-β complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013 ; 288 (8). 5914-5926
32. Vuletic S, Li G, Peskind ER, et al. Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis. 2008 ; 15 (3). 409-417
33. Azumi M, Ishizuka S, Fujii M, Sasaki H. Antipsychotics and cognitive function. Psychogeriatrics. 2011 ; 11 (2). 79-82
34. Vigen CLP, Mack WJ, Keefe RSE, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 ; 168 (8). 831-839
35. Ballard C, Patel A, Oyebode F, Wilcock G. Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Age Ageing. 1996 ; 25 (3). 209-213
36. Chapman RM, Mapstone M, Gardner MN, et al. Women have farther to fall: gender differences between normal elderly and alzheimer's disease in verbal memory engender better detection of Alzheimer's disease in women. J Int Neuropsychol Soc. 2011 ; 17 (4). 654-662
37. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012 ; 11 (11). 1006-1012